23705-39-7

Basic information

• Product Name: N-isobutylbenzenesulfonamide
• Synonyms: N-isobutylbenzenesulfonamide
• CAS NO: 23705-39-7
• Molecular Formula: C₁₀H₁₅NO₂S
• Molecular Weight: 213.2966
• Mol File: 23705-39-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-isobutylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-isobutylbenzenesulfonamide(23705-39-7)
• EPA Substance Registry System: N-isobutylbenzenesulfonamide(23705-39-7)

Safety Data

• Hazardous Substances Data: 23705-39-7(Hazardous Substances Data)

Upstream product

• 78-81-9 isobutylamine 
• 80-17-1 benzenesufonyl hydrazide 
• 1616490-50-6 C₁₇H₂₁NO₂S 
• 98-11-3 benzenesulfonic acid 
• 98-09-9 benzenesulfonyl chloride 
• 7242-84-4 N-isobutanoyl-benzenesulfonamide 

Downstream Products

• 79506-20-0 N-isobutyl-N-nitro-benzenesulfonamide 

Relevant articles and documents

AEROBIC OXIDATIVE SYNTHESIS OF SULFONAMIDE USING Cu CATALYST

The present invention relates to a method for oxidative synthesis of sulfonamides using copper catalysts. , Oxygen (O) is used. 2 The oxidative synthesis of sulfonamides (1) comprises reacting a 2 th or sulfonyl hydrazide primary amine with a sulfonyl hydrazide (sulfonamide) with a copper catalyst on a solvent under the conditions in which the sulphonamide is fed. The oxidation coupling of the present invention showed extensive substrate ranges in an amine comprising a 2 primary amine, 1 primary amine and amine hydrochloride salt. It is worth notable that non-reactive aliphatic sulfonyl hydrazides in previously reported anaerobic systems can be used for the aerobic oxidation coupling of the present invention. The oxidation coupling of the present invention has been more effective on large scale.

Solid supported Hayashi–J?rgensen catalyst as an efficient and recyclable organocatalyst for asymmetric Michael addition reactions

A comparison of three different catalytic systems for the efficient, asymmetric synthesis of N-({(3R,4R)-4-[(benzyloxy)methyl]pyrrolidin-3-yl}methyl)-N-(2-methylpropyl)benzenesulfonamide 1 (BZN) is described. The presented strategy is based on the organocatalytic Michael addition of aldehyde 2 to trans-nitroalkene 3, and subsequent reductive cyclization. High yields, enantio-, and diastereoselectivities were achieved in the Michael addition by application of a POSS- or Wang resin-supported Hayashi–J?rgensen catalyst.

Hydroxamates: Relationships between structure and plasma stability

Hydroxamates are valuable tools for chemical biology as well as interesting leads for medicinal chemistry. Although many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure-plasma stability for hydroxamates. We define some structural rules to predict or improve the plasma stability in the preclinical stage.